Drug intelligence / Profile preview

Exendin-4[E17C, E24C]-S2

Development stage: Preclinical
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Exendin-4[E17C, E24C]-S2 is a novel long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist engineered by introducing cysteine substitutions at positions 17 and 24 of the exendin-4 peptide and conjugating it with an S2 staple. This modification enhances its stability and prolongs its half-life in vivo. The drug exhibits dose-dependent reductions in food intake and body weight in preclinical models, with efficacy comparable to semaglutide. Its primary mechanism of action is as a GLP-1 receptor agonist, leading to improved glycemic control and potential benefits for obesity management[1][6]. The developer appears to be an academic or research institution based on available literature.

Other names: Ex-4[E17C, E24C]-S2

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on Exendin-4[E17C, E24C]-S2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exendin-4[E17C, E24C]-S2.

Explore the full profile